PITTSBURGH, July 26 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that U.S. Patent No. 7,070,808 was issued to its subsidiary, Mylan Technologies Inc. (MTI), on July 4, 2006. The '808 Patent contains one or more claims which cover the EMSAM^® transdermal product, which is indicated for the treatment of major depressive disorder.

MTI granted Somerset Pharmaceuticals Inc. an exclusive license to the '808 Patent with respect to the transdermal delivery of selegiline, the active ingredient in EMSAM^®. Bristol-Myers Squibb distributes the EMSAM^® product which is manufactured by MTI for Somerset.

EMSAM^® is a registered trademark of Somerset Pharmaceuticals, Inc.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit www.mylan.com.

SOURCE Mylan Laboratories Inc.
07/26/2006
CONTACT: Patrick Fitzgerald of Mylan Laboratories Inc., +1-724-514-1811,
Patrick.Fitzgerald@mylanlabs.com
Web site: http://www.mylan.com
(MYL)